Literature DB >> 30697353

Erectile Dysfunction and Ischaemic Heart Disease.

Abdalla Ibrahim1, Mohamed Ali2, Thomas J Kiernan1, Austin G Stack3.   

Abstract

Erectile dysfunction (ED) is a common disorder that affects the quality of life of many patients. It is prevalent in more than half of males aged over 60 years. Increasing evidence suggests that ED is predominantly a vascular disorder. Endothelial dysfunction seems to be the common pathological process causing ED. Many common risk factors for atherosclerosis such as diabetes, hypertension, smoking, obesity and hyperlipidaemia are prevalent in patients with ED and so management of these common cardiovascular risk factors can potentially prevent ED. Phosphodiesterase type 5 inhibitors provide short-term change of haemodynamic factors to help initiate and maintain penile erection. They have been shown to be an effective and safe treatment strategy for ED in patients with heart disease, including those with ischaemic heart disease and hypertension.

Entities:  

Keywords:  Atherosclerosis; endothelial dysfunction; erectile dysfunction; ischaemic heart disease; phosphodiesterase inhibitors

Year:  2018        PMID: 30697353      PMCID: PMC6331774          DOI: 10.15420/ecr.2017.21.3

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN: 1758-3756


  77 in total

Review 1.  Erectile dysfunction.

Authors:  T F Lue
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

Review 2.  Prognostic implications of endothelial dysfunction: does it mean anything?

Authors:  V Schächinger; A M Zeiher
Journal:  Coron Artery Dis       Date:  2001-09       Impact factor: 1.439

Review 3.  The link between smoking and impotence: two decades of evidence.

Authors:  T O Tengs; N D Osgood
Journal:  Prev Med       Date:  2001-06       Impact factor: 4.018

4.  Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease.

Authors:  A M Olsson; C A Persson
Journal:  Int J Clin Pract       Date:  2001-04       Impact factor: 2.503

5.  Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type II diabetes.

Authors:  P J Chowienczyk; S E Brett; N K Gopaul; D Meeking; M Marchetti; D L Russell-Jones; E E Anggård; J M Ritter
Journal:  Diabetologia       Date:  2000-08       Impact factor: 10.122

Review 6.  Cardiovascular effects of sildenafil citrate and recommendations for its use.

Authors:  R A Kloner; R M Zusman
Journal:  Am J Cardiol       Date:  1999-09-09       Impact factor: 2.778

7.  Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.

Authors:  R Fogari; A Zoppi; L Poletti; G Marasi; A Mugellini; L Corradi
Journal:  Am J Hypertens       Date:  2001-01       Impact factor: 2.689

Review 8.  Psychogenic erectile dysfunction. Classification and management.

Authors:  R C Rosen
Journal:  Urol Clin North Am       Date:  2001-05       Impact factor: 2.241

Review 9.  Penile erection and cardiac risk: pathophysiologic and pharmacologic mechanisms.

Authors:  K Andersson; C Stief
Journal:  Am J Cardiol       Date:  2000-07-20       Impact factor: 2.778

10.  Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.

Authors:  C R Conti; C J Pepine; M Sweeney
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

View more
  6 in total

1.  Erectile dysfunction and coronary artery calcification in incident dialysis patients.

Authors:  Neil Roy; Sylvia Eleni Rosas
Journal:  J Nephrol       Date:  2021-03-08       Impact factor: 3.902

Review 2.  Mean platelet volume as a predictive marker of erectile dysfunction: a meta-analysis.

Authors:  Nur Rasyid; Maruto Harjanggi; Widi Atmoko; Ponco Birowo
Journal:  Int J Impot Res       Date:  2022-01-29       Impact factor: 2.896

3.  Efficacy of the Orally Disintegrating Strip Sildenafil for the Treatment of Erectile Dysfunction: A Prospective, Randomized Trial.

Authors:  Premsant Sangkum; Kun Sirisopana; Wijittra Matang; Yada Phengsalae; Panuwat Lertsithichai; Chinnakhet Ketsuwan; Wachira Kochakarn; Wisoot Kongchareonsombat
Journal:  Sex Med       Date:  2021-10-26       Impact factor: 2.491

4.  Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes.

Authors:  Haifa Maalmi; Christian Herder; Gidon J Bönhof; Klaus Strassburger; Oana-Patricia Zaharia; Wolfgang Rathmann; Volker Burkart; Julia Szendroedi; Michael Roden; Dan Ziegler
Journal:  Diabetologia       Date:  2021-11-20       Impact factor: 10.460

5.  Effect of tadalafil combined with atorvastatin on hemodynamics and sexual function in middle-aged and elderly patients with hyperlipidemia complicated with erectile dysfunction.

Authors:  Lei Du; Jiang-Hua Jia; Wen-Yong Xue; Jin-Chun Qi
Journal:  Pak J Med Sci       Date:  2021 Nov-Dec       Impact factor: 1.088

Review 6.  Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses.

Authors:  Hadi Mostafaei; Keiichiro Mori; Sakineh Hajebrahimi; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  BJU Int       Date:  2021-01-09       Impact factor: 5.588

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.